News

The World Health Organization is now recommending that countries include an HIV drug newly approved for prevention, ...
The Trump administration agreed to exempt a global AIDS-relief program from spending cuts in the rescissions package.
The country isn’t getting extra money from the Global Fund to Fight Aids, TB and Malaria; it has to use cash from a grant it ...
(Reuters) -Gilead Sciences and the Global Fund to Fight AIDS, Tuberculosis and Malaria said on Wednesday they had finalized ...
The U.S. Senate is due to begin voting on Tuesday on President Donald Trump's request to slash billions in spending on ...
This isn’t about managing the AIDS pandemic. It’s about ending it — and letting a new generation grow and thrive free of its ...
Gilead Sciences, Inc. (NASDAQ:GILD) is a biopharmaceutical company that discovers, develops, and commercializes medicines in ...
Gilead announced a deal to get its groundbreaking HIV prevention drug to lower income countries. Notably, the deal does not ...
As expected, the new recommendations that the World Health Organization (WHO) issued for HIV and sexually transmitted ...
The Global Fund to Fight AIDS, Tuberculosis and Malaria (the Global Fund) has announced that it has signed an access agreement with Pharmaceutical Company Gilead Sciences to procure lenacapavir, a ...
Until recently, the UN was on track to meet its target of ending AIDS as a public health threat by 2030. But with the U.S. rapidly scaling back foreign aid contributions, the UN has released a new ...
Global health leaders and advocates challenged attendees of IAS to support the work of the partnerships that are creating patient-focused innovations for HIV prevention and treatment.